Wilson Disease

Wilson disease (WD) is an autosomal recessive disorder of copper metabolism caused by pathogenic variants in the ATP7B gene, leading to toxic copper accumulation predominantly in the liver and brain ^[1]D5[6]D5. This section establishes the precise disease definition, its classification within the hepatocellular-versus-cholestatic spectrum, and the current consensus nomenclature that underpins the rest of this article.

Also Called / Synonyms

• Wilson disease (WD)
• Hepatolenticular degeneration (historical term)
• Copper storage disease
• ATP7B-related copper toxicosis

Disease Definition and Core Concept

The pathognomonic defect is a loss-of-function mutation in ATP7B, which encodes a copper-transporting P-type ATPase essential for biliary copper excretion and incorporation of copper into ceruloplasmin ^[1]D5[8]C4. When this transporter fails, copper accumulates first in hepatocytes, then spills into the systemic circulation, depositing in the brain, cornea (Kayser-Fleischer rings), kidneys, and other tissues ^[1]D5[6]D5. WD sits squarely in the hepatocellular disease spectrum: the primary lesion is hepatic copper overload, not a cholestatic defect in bile flow. The cholestatic phenotypes seen in some patients are a consequence of advanced liver injury, not a primary biliary disorder.

Classification of Clinical Phases & Stages

To avoid ambiguity, the following terms are used throughout this article as defined by international consensus guidelines from AASLD, EASL, and ESPGHAN ^[1]D5[6]D5:

Important distinctions: "Pre-symptomatic" replaces the older term "asymptomatic" to emphasize that these patients harbour disease that will progress without treatment ^[1]D5. "Acute decompensated WD" is distinct from compensated cirrhosis in WD, the former is a medical emergency requiring immediate transplant evaluation ^[5]C4.

Clinical Significance

WD affects approximately 1 in 30,000 to 1 in 50,000 live births globally ^[1]D5. If untreated, it is uniformly fatal; with early diagnosis and lifelong chelation or zinc therapy, most patients achieve normal life expectancy ^[2]B2a[6]D5. It is the classic example of a treatable inherited metabolic liver disease and a diagnostic priority in any young patient with unexplained liver disease, neurologic movement disorder, or psychiatric disturbance.

Pearl: Wilson disease is a treatable disorder of copper overload; early diagnosis and treatment prevent disease progression and allow normal life expectancy, making it a diagnostic priority in every young patient with unexplained liver or neurologic disease ^{[1]D5[2]B2a[6]D5}.

The pathogenic cascade in Wilson disease begins with failure of biliary copper excretion due to loss-of-function mutations in ATP7B, a P-type copper-transporting ATPase. Under normal conditions, ATP7B transports copper into the trans‑Golgi network for incorporation into ceruloplasmin and, when cytosolic copper rises, relocates to the canalicular membrane to facilitate biliary excretion ^[9]A1b[14]D5. Mutations in ATP7B disrupt this trafficking or catalytic activity, causing copper to accumulate first in the liver, then in the brain and other tissues. The resulting cellular toxicity drives a sequence of hepatocellular injury, steatosis, inflammation, stellate‑cell activation, and progressive fibrosis that ultimately culminates in cirrhosis and portal hypertension . Every clinical manifestation, from Kayser-Fleischer rings to extrapyramidal signs, can be traced back to copper‑induced organ damage at the molecular and cellular level.

Hepatic Copper Accumulation and the Initial Insult

Copper enters hepatocytes via the high‑affinity copper transporter CTR1 (SLC31A1). Once inside, copper is chaperoned to ATP7B by ATOX1. ATP7B then moves copper into the Golgi for ceruloplasmin synthesis or, when copper is abundant, translocates to the bile canaliculus for excretion ^[9]A1b[12]D5. In Wilson disease, mutant ATP7B, whether partially active or completely inactive, cannot perform this export efficiently. Hepatic copper content rises progressively, exceeding the capacity of protective mechanisms such as metallothionein binding. Free copper catalyzes Fenton‑type reactions, generating reactive oxygen species (ROS) that peroxidate membrane lipids and damage mitochondria ^[13]B3b. Mitochondrial dysfunction in turn impairs fatty acid β‑oxidation, leading to macrovesicular steatosis, often the earliest histological finding in Wilson disease, sometimes indistinguishable from non‑alcoholic fatty liver disease ^[13]B3b. Genetic modifiers such as the PNPLA3 I148M variant (rs738409) further increase steatosis severity, accounting for some of the phenotypic variability among patients ^[13]B3b.

Progression from Steatosis to Fibrosis and Cirrhosis

Sustained copper‑induced oxidative stress triggers hepatocyte apoptosis and necrosis, releasing damage‑associated molecular patterns (DAMPs) that activate Kupffer cells and hepatic stellate cells (HSCs) ^[11]D5. Activated HSCs transdifferentiate into myofibroblasts, secreting collagen‑rich extracellular matrix that progressively replaces functional parenchyma. Autophagy, a quality‑control pathway that normally degrades damaged organelles and lipid droplets, becomes overwhelmed or dysfunctional in Wilson disease hepatocytes, further aggravating steatosis and inflammation ^[11]D5. The net result is a self‑amplifying fibrotic response. Over years to decades (or faster in early‑onset pediatric cases ^[17]B2b), bridging fibrosis and nodular regeneration produce cirrhosis and, ultimately, portal hypertension . Importantly, nuclear receptor dysregulation also contributes to disease progression. Liver X receptor (LXR)/retinoid X receptor (RXR) heterodimer signalling is suppressed in both human Wilson disease and Atp7b⁻/⁻ mouse liver; treatment of mice with the LXR agonist T0901317 ameliorated hepatic steatosis and fibrosis without lowering hepatic copper content, indicating that LXR/RXR pathway activation can partially rescue copper‑independent injury ^[10]D5.

Neurological and Psychiatric Pathogenesis

Once the liver can no longer sequester excess copper, non‑ceruloplasmin‑bound (free) copper spills into the circulation and crosses the blood-brain barrier, preferentially accumulating in the basal ganglia, thalamus, brainstem, and cerebellum ^[18]D5. Copper disrupts neuronal mitochondrial function, induces oxidative stress, and promotes protein aggregation. In the putamen and caudate, this leads to neuronal loss, spongiform degeneration, and reactive gliosis, findings that correlate with the characteristic movement disorders (dystonia, parkinsonism , tremor) and psychiatric symptoms (depression, psychosis, personality changes). Resting‑state electroencephalography reveals abnormal microstate dynamics (increased duration of microstate C, decreased of microstates B and D) that reflect disrupted large‑scale neural network coordination, providing a quantifiable signature of neurological involvement ^[21]B3b. The Kayser-Fleischer rings, copper deposition in Descemet’s membrane of the cornea, are a direct biomarker of CNS copper overload but also indicate systemic copper excess; they appear as golden‑brown or greenish rings at the corneal limbus and are pathognomonic when present ^[18]D5.

Extra‑Hepatic, Extra‑Neuronal Copper Deposition

Copper also deposits in the heart, kidneys, eyes (other than cornea), and bones. Cardiac involvement manifests as left ventricular hypertrophy , diastolic dysfunction, and conduction abnormalities; three cases of sudden death have been reported, highlighting the potential for arrhythmogenic cardiomyopathy ^[15]C4. Renal tubular dysfunction results from copper accumulation in proximal tubule cells, causing aminoaciduria, phosphaturia, and renal tubular acidosis ^[18]D5. Ocular copper deposition may also involve the lens (sunflower cataract) and retina ( retinitis pigmentosa ‑like changes) ^[19]C4, though retinal abnormalities are rare. The mechanism of copper‑driven injury in these organs mirrors that in the liver: ROS generation, mitochondrial impairment, and cellular stress.

Genetic and Molecular Determinants of Phenotypic Variability

The clinical heterogeneity of Wilson disease, ranging from asymptomatic siblings to fulminant hepatic failure to isolated neuropsychiatric disease, stems from the functional diversity of ATP7B mutations and from genetic modifiers. Over 900 ATP7B mutations have been described; they can be classified by their effect on protein function: no copper transport activity (e.g., H1069Q), partial activity with mislocalization (e.g., R778Q, G1061E), or abnormal trafficking in polarized cells (e.g., C‑terminal mutations S1423N, S1426I, T1434M that impair Golgi exit selectively in polarized hepatocytes) ^[14]D5[16]D5. The degree of residual copper excretion capacity determines how rapidly copper accumulates and at what age symptoms appear ^[14]D5. Additional modifiers include PNPLA3 I148M (worsening steatosis) ^[13]B3b and polymorphisms in zinc transporter ZnT1 (SLC30A1), which can export copper at the basolateral membrane and may modulate hepatic copper levels ^[20]D5. Furthermore, the LXR/RXR pathway ^[10]D5 and autophagic capacity ^[11]D5 represent modifiable cellular responses that influence disease progression independently of copper burden.

Controversies and Guideline Disagreement

Copper overload is the primary driver, but is it sufficient to explain all injury? Some data suggest that copper‑independent pathways, such as LXR/RXR dysregulation and autophagy failure, contribute substantially to disease severity, raising the question of whether pure copper chelation adequately addresses all pathogenic mechanisms. While EASL and AASLD guidelines uniformly recommend copper‑directed therapy (chelators plus zinc), the potential role of LXR agonists or autophagy‑enhancing agents as adjunctive treatments remains unexplored in clinical trials ^[10]D5[11]D5.

Pearl: Copper accumulation in the liver triggers a cascade of mitochondrial dysfunction, steatosis, LXR/RXR pathway suppression, and autophagy failure that drives progressive fibrosis; neurological damage follows once free copper deposits in the basal ganglia, and genetic modifiers (PNPLA3, ATP7B mutation type) account for much of the phenotypic variability.

Sub‑section: Key Molecular Steps (Numbered Chain)

1. Defective copper export - ATP7B mutations (e.g., H1069Q, R778Q, C‑terminal truncations) prevent biliary copper excretion, raising cytosolic copper ^{[9]A1b[14]D5[16]D5}.
2. Oxidative stress and mitochondrial injury - Free copper catalyzes ROS production, depletes glutathione, and damages mitochondrial DNA and membranes, impairing fatty acid oxidation ^[13]B3b.
3. Steatosis and hepatocyte necrosis - Impaired β‑oxidation leads to macrovesicular steatosis; ROS‑mediated apoptosis releases DAMPs that activate Kupffer cells ^{[11]D5[13]B3b}.
4. Hepatic stellate cell activation - DAMPs and inflammatory cytokines (TNF‑α, TGF‑β) transdifferentiate stellate cells into myofibroblasts, which deposit collagen ^[11]D5.
5. Fibrosis and cirrhosis - Progressive matrix deposition leads to bridging fibrosis, nodule formation, and portal hypertension.
6. Systemic copper spillover - Once hepatic storage capacity is exhausted, free copper enters the circulation and deposits in brain (basal ganglia), eyes (cornea, lens, retina), heart, and kidneys ^{[15]C4[18]D5[19]C4}.
7. Neurological network disruption - Basal ganglia copper accumulation causes neuronal loss, gliosis, and altered EEG microstate dynamics, manifesting as extrapyramidal and psychiatric syndromes ^{[18]D5[21]B3b}.

The global prevalence of Wilson disease is estimated at 1 in 30,000 to 1 in 50,000 live births, corresponding to a carrier frequency of approximately 1 in 90 ^[29]D5. These figures, however, likely underestimate the true burden because of variable penetrance, incomplete case ascertainment, and the absence of universal newborn screening in most regions. In the Austrian cohort of 229 patients diagnosed between 1961 and 2013, the mean age at diagnosis was 14.8 years, with a slight female predominance (55%) ^[25]B2b. The disease is pan-ethnic but shows regional clustering; systematic reviews from the Arab world report similar prevalence ranges but highlight a high rate of consanguinity and a distinct mutation spectrum ^[29]D5. Temporal trends are difficult to assess due to diagnostic delays, but improved awareness and genetic testing have increased detection rates over recent decades.

Genetic and Modifiable Risk Factors

Wilson disease is an autosomal recessive disorder caused by biallelic pathogenic variants in ATP7B (chromosome 13q14.3). Over 900 mutations have been described, with the H1069Q variant accounting for 30-60% of alleles in European populations ^[29]D5. No environmental or lifestyle factors are known to cause the disease, but several comorbidities modify its clinical expression and progression.

HBV coinfection is a particularly important modifier. In a large retrospective study of 915 WD patients, current HBV infection was present in 2.1% (95% CI 1.2-3.0%) and past infection in 9.2% (95% CI 7.3-11.1%) ^[23]B2b. Those with dual pathology had significantly higher bilirubin, INR, and Model for End-Stage Liver Disease scores, indicating accelerated liver injury ^[23]B2b. Similarly, anemia (hemoglobin <12 g/dL in women, <13 g/dL in men) was found in 16.7% of a Chinese WD cohort and independently predicted hepatic decompensation (OR 2.8) ^[7]B2b. The platelet-to-white blood cell ratio (PWR <26.3) has been proposed as a noninvasive marker of fibrosis severity and progression risk ^[28]B3b.

Special Populations

Pediatric acute liver failure (PALF): Wilson disease accounts for approximately 5-10% of PALF cases, but it is frequently misdiagnosed as indeterminate. A learning collaborative that promoted age-specific diagnostic testing increased the identification of WD among PALF patients, reducing the proportion of indeterminate diagnoses ^[26]B2b.

Pregnancy: Women with WD have higher rates of adverse pregnancy outcomes, including miscarriage (pooled prevalence 18%), preterm birth (12%), and low birth weight (8%) ^[22]A1a. Importantly, untreated WD carries even greater risks; chelation therapy (trientine or zinc) during pregnancy is associated with better outcomes and should be continued ^[22]A1a.

Liver transplantation : Among patients who progress to end-stage liver disease, post-transplant survival is excellent. A meta-analysis of 27 studies reported 1-year survival of 92% and 5-year survival of 88% ^[27]A1a. Neuropsychiatric symptoms improve in most patients after transplantation, though residual deficits may persist ^[27]A1a.

Pearl: Wilson disease is rare but underdiagnosed; a high index of suspicion is warranted in any patient with unexplained liver disease, neuropsychiatric symptoms, or a family history. Coinfection with HBV and the presence of anemia or low PWR identify patients at risk for more rapid progression ^{[7]B2b[23]B2b[28]B3b}.

Hepatic manifestations are the presenting feature in approximately 40-50% of index patients, with neurological symptoms accounting for another 30-40% ^[33]B2b. The remaining patients present with mixed hepatic and neurological disease or are identified asymptomatically through family screening. The clinical spectrum ranges from incidental transaminase elevation to acute liver failure with Coombs-negative hemolytic anemia, and from subtle tremor to severe dystonia with bulbar compromise.

Presenting Symptoms

Hepatic presentation often begins insidiously. Children and adolescents may have asymptomatic elevation of aminotransferases or hepatic steatosis, which is one of the earliest features in pediatric Wilson disease ^[40]B3b. Others present with acute hepatitis, chronic hepatitis, or cirrhosis. Acute liver failure (ALF) is a dramatic presentation, typically in young patients, and is frequently accompanied by Coombs-negative hemolytic anemia due to copper-induced erythrocyte membrane damage. Decompensated cirrhosis manifests with ascites , variceal bleeding, jaundice, and hepatic encephalopathy . In the large Austrian cohort, hepatic presentation was more common in females and younger patients ^{[25]B2b[33]B2b}.

Neurological presentation typically emerges in the second to third decade, often with a gradual onset over months. The most common initial symptoms are dysarthria (slurred speech), drooling, tremor (often a characteristic "wing-beating" tremor of the arms), and gait disturbance. Dystonia (focal or generalized), chorea, athetosis, and parkinsonism (rigidity, bradykinesia, postural instability) may develop. Ataxia and dysdiadochokinesia reflect cerebellar involvement. Psychiatric symptoms, depression, anxiety, irritability, personality changes, psychosis, and cognitive decline, can precede or accompany neurological signs and are often misattributed to primary psychiatric disorders.

Other organ involvement includes renal tubular dysfunction ( Fanconi syndrome : glycosuria, aminoaciduria, phosphaturia), skeletal abnormalities (osteoporosis, osteomalacia , arthropathy), cardiac manifestations (cardiomyopathy, arrhythmias), endocrine disturbances (delayed puberty, amenorrhea, infertility), and dermatologic findings (livido reticularis, hyperpigmentation). Kayser-Fleischer rings, copper deposition in the Descemet membrane of the cornea, are present in approximately 95% of patients with neurological Wilson disease and 50% of those with hepatic presentation ^[41]C4. Sunflower cataracts are a rarer ocular finding.

Neurological Examination Findings

A structured neurological examination is essential. Cranial nerves: Kayser-Fleischer rings are best seen on slit-lamp examination; sunflower cataracts may be visible on direct ophthalmoscopy. Ocular motor abnormalities include saccadic intrusions, nystagmus, and impaired smooth pursuit. Motor system: Tremor is often the first sign, a coarse, irregular, proximal "wing-beating" tremor that worsens with sustained posture. Dystonia may be focal (e.g., cervical dystonia , blepharospasm) or generalized. Chorea and athetosis are less common. Parkinsonism presents with cogwheel rigidity, bradykinesia, and postural instability. Cerebellar signs include dysmetria, dysdiadochokinesia, and ataxic gait. Reflexes: Hyperreflexia and extensor plantar responses (Babinski sign) may occur with corticospinal tract involvement, but reflexes are often normal. Sensory examination is typically normal. Bulbar function: Dysarthria (spastic, ataxic, or hypokinetic) and dysphagia are common and can lead to aspiration. FVC < 15 mL/kg or declining forced vital capacity signals impending respiratory failure and should prompt consideration of intubation. Autonomic dysfunction (orthostatic hypotension, sweating abnormalities) may occur in advanced disease.

Phenotypic Variants

Red Flags

• Rapidly progressive neurological symptoms (dystonia, dysarthria, dysphagia) within the first 3 months of therapy, early neurological worsening occurs in 26.1% of patients with neurological or mixed presentation ^[4]B2b.
• Acute liver failure with Coombs-negative hemolytic anemia, consider Wilson disease as the cause.
• Unexplained psychiatric symptoms (depression, psychosis, personality change) in a young adult.
• Kayser-Fleischer rings on slit-lamp examination.
• Family history of Wilson disease or unexplained liver disease.

Atypical Presentations

Wilson disease can mimic many conditions. Isolated psychiatric disease ( schizophrenia , bipolar disorder) may precede neurological signs by years. Renal tubular acidosis or Fanconi syndrome can be the sole manifestation. Hemolytic anemia without overt liver failure is a rare but classic presentation. Skeletal abnormalities (osteoporosis, spontaneous fractures) may prompt rheumatologic evaluation. Cardiac arrhythmias or cardiomyopathy can be the first clue. Endocrine presentations include delayed puberty, amenorrhea, or infertility. Neurologically, patients may present with isolated tremor, isolated dysarthria, or isolated gait ataxia, leading to misdiagnosis as essential tremor , multiple sclerosis, or cerebellar degeneration. Asymptomatic individuals with elevated transaminases are often identified through family screening or incidental laboratory findings.

Pearl: The clinical phenotype of Wilson disease is highly variable and influenced by age, sex, and ATP7B genotype, but not by mutation type alone ^{[33]B2b[36]A1a}; a high index of suspicion is required for any young patient with unexplained liver disease, hemolytic anemia, or neuropsychiatric symptoms, as early treatment dramatically improves outcomes ^[25]B2b.

The diagnostic evaluation of Wilson disease (WD) rests on a tiered strategy combining clinical examination, biochemical copper studies, and molecular confirmation, anchored by the Leipzig scoring system (see Table 1). No single test is sufficient in isolation; the diagnosis is established when the cumulative evidence reaches a score of ≥4 points ^{[31]C4[37]A1c}. The gold standard for definitive diagnosis remains ATP7B mutation analysis identifying biallelic pathogenic variants, though this is supplemented by quantitative liver copper measurement when genetic results are inconclusive ^{[46]B2b[55]B2b}.

Step 1: Clinical Suspicion and Initial Screening

The diagnostic pathway begins with recognizing WD in any patient aged 3-55 years presenting with unexplained liver disease (elevated aminotransferases, steatosis, cirrhosis), neurological symptoms (tremor, dysarthria, dystonia), or psychiatric disturbances (depression, personality change) ^{[33]B2b[18]D5}. Kayser-Fleischer (KF) rings, copper deposition in Descemet's membrane of the cornea, remain a highly specific sign when present, detected by slit-lamp examination. In one large Chinese cohort of 529 symptomatic patients, KF rings were present in 89.4% of neurological-presentation patients but only 53.7% of those with hepatic presentation ^[53]B2b. Their absence does not exclude WD, particularly in children and adults with purely hepatic disease ^{[31]C4[53]B2b}.

Step 2: Biochemical Copper Studies

Serum ceruloplasmin is the first-line screening test. A level <20 mg/dL (by nephelometry) supports WD, but performance varies by clinical context. In a prospective study of 140 acute liver failure (ALF) patients, nephelometric ceruloplasmin <20 mg/dL had only 56% sensitivity and 63% specificity for WD-associated ALF ^[42]B2b. The oxidase activity method yielded even lower sensitivity (21%) ^[42]B2b. In children with mild liver disease and elevated transaminases, a cutoff of <14 mg/dL provided 93% sensitivity and 100% specificity compared to healthy controls, but specificity fell to 79% against other liver diseases ^[3]B3b. Concomitant acute-phase response can falsely elevate ceruloplasmin; a normal level does not rule out WD. Measuring 24-hour urinary copper excretion is the next step. A basal excretion >100 μg/24 h (1.6 μmol/24 h) is classic for symptomatic WD ^[37]A1c. In children with mild disease, a cutoff of >40 μg/24 h provided 85% sensitivity and 96% specificity for diagnosis ^[3]B3b. The penicillamine challenge test (giving 500 mg D-penicillamine orally at the start and again 12 hours later, collecting urine for 24 hours) increases sensitivity; excretion >1600 μg/24 h supports WD, though this test is less commonly used today ^[31]C4.

Serum copper is not diagnostic in isolation: total copper is low in WD due to low ceruloplasmin, but in ALF-WD, massive hepatic necrosis releases copper, yielding total serum copper >200 μg/dL in nearly all such patients ^[42]B2b. The non-ceruloplasmin-bound copper (free copper) can be calculated (total copper - [3.15 × ceruloplasmin in mg/dL]) and a value >25 μg/dL is abnormal; however, its calculation amplifies measurement errors ^[45]B2b. Direct measurement of exchangeable copper (CuEX) and the relative exchangeable copper (REC = CuEX / total copper × 100) are emerging as robust biomarkers. A REC >18.5% has been proposed as a diagnostic threshold with high sensitivity in treatment-naïve patients ^{[43]B2b[37]A1c}. In the ALF setting, the ALT:AST ratio is also useful: a ratio <1 (AST higher than ALT) plus a alkaline phosphatase (ALP):total bilirubin ratio <4 supports ALF-WD ^[45]B2b.

Step 3: Leipzig Scoring System

The Leipzig criteria, endorsed by EASL and AASLD, assign points across six domains ^{[31]C4[37]A1c}:

Interpretation: Score ≥4 establishes the diagnosis; score 3 is suggestive and requires further evaluation; score ≤2 makes WD unlikely ^{[31]C4[37]A1c}.

Step 4: Genetic Testing

ATP7B sequencing is the confirmatory gold standard and should be performed in all cases where suspicion remains after biochemical testing or when results are equivocal ^{[46]B2b[55]B2b[49]B2b}. The gene spans 21 exons; mutation hotspots include exons 8, 12, and 14, but comprehensive sequencing (including intronic regions) is necessary because up to 20% of clinically diagnosed patients with Leipzig score ≥4 have zero or only one identifiable ATP7B variant by standard methods ^[55]B2b. In such cases, whole-genome sequencing can detect deep intronic or structural variants ^[55]B2b. A novel direct assay measuring ATP7B protein concentration from dried blood spots (by mass spectrometry of surrogate peptides) showed 96% sensitivity and 94% specificity in a multi-center cohort of 264 WD patients and 150 controls, making it a promising second-line tool ^[46]B2b. Multi-gene panels that include ATP7B plus copper-related genes (e.g., COMMD1, ATOX1) can identify phenocopies like progressive familial intrahepatic cholestasis type 3 (PFIC3) , which can present with hepatic copper accumulation and elevated urinary copper, leading to misdiagnosis as WD ^{[48]D5[49]B2b}.

Step 5: Liver Biopsy and Copper Quantification

Liver biopsy is not required for diagnosis when genetic testing is positive or when clinical-biochemical criteria yield a Leipzig score ≥4. It is reserved for cases where genetic results are uninformative (single variant or none) and biochemical tests are borderline ^[55]B2b. A liver copper content >250 μg/g dry weight (normal <50 μg/g) is diagnostic ^[3]B3b. Biopsy also provides histologic grading of steatosis, inflammation, and fibrosis. Steatosis, often macrovesicular or mixed, is present early and may be indistinguishable from NAFLD; the PNPLA3 rs738409 G allele is an independent modifier of steatosis severity in WD ^[13]B3b. Cirrhosis may be present even in children ^[3]B3b.

Step 6: Imaging

Abdominal ultrasound is the first imaging modality used to assess hepatic steatosis, cirrhosis, and portal hypertension . Transient elastography (FibroScan) provides non-invasive fibrosis staging with correlation to histologic stage in WD ^[25]B2b. Brain MRI (with T2-weighted and FLAIR sequences) is indicated in any patient with neurological or psychiatric symptoms. Characteristic findings include hyperintensity in the basal ganglia (putamen, globus pallidus, caudate), thalamus, and brainstem (especially the midbrain, the "face of the giant panda" sign in the substantia nigra) ^[18]D5. MRI can also guide prognosis: presence of brainstem involvement correlates with worse neurological outcomes ^[4]B2b.

Step 7: Differential Diagnosis and Pitfalls

Several conditions mimic WD and must be excluded, particularly when genetic testing is incomplete:

• Autoimmune hepatitis (AIH): Up to 31.5% of treatment-naïve WD children have false-positive autoantibodies (anti-smooth muscle, ANA) and elevated IgG (>1.1×ULN in 82.3%), leading to misclassification as AIH by simplified criteria ^[54]B3b. Copper markers should be checked in any child with suspected AIH who has atypical features (low aminotransferases, hemolysis , low ALP).
• PFIC3: Caused by biallelic ABCB4 mutations, PFIC3 presents with cholestasis, elevated serum copper, and urinary copper that can meet Leipzig criteria ^[48]D5. Genetic panels that include ABCB4 and other cholestasis genes resolve this mimic ^[49]B2b.
• Acute liver failure from other causes: As noted above, ALF-WD is distinguished by the ALP:bilirubin ratio <4 and ALT:AST <1 ^[45]B2b.
• Citrullinemia type I and other urea cycle defects can present with ALF and low ceruloplasmin, mimicking WD ^[47]C4. Plasma amino acids and ammonia levels differentiate these.
• Ceruloplasmin measurement variability: Inflammatory states elevate ceruloplasmin; low values also occur in Menkes disease, protein-losing enteropathy , and severe malnutrition.

Diagnostic Algorithm (Summarized)

1. Screen with slit-lamp for KF rings and measure serum ceruloplasmin + 24-h urinary copper in any patient with unexplained liver or neuropsychiatric disease.
2. Calculate the Leipzig score using available clinical, biochemical, and imaging data.
3. If score ≥4: Confirm with ATP7B sequencing; initiate treatment. Biopsy is unnecessary unless genetic results are pending and clinical urgency requires immediate therapy.
4. If score 2-3: Perform ATP7B sequencing + multi-gene panel for phenocopies. Consider liver biopsy for copper quantification. Measure REC if available.
5. If score ≤2 and suspicion remains (e.g., family history, atypical presentation): Refer to specialist center for whole-genome sequencing, ATP7B protein assay, or repeat biopsy ^{[46]B2b[55]B2b}.
6. In all ALF cases: If clinical features suggest WD (Coombes-negative hemolysis, low ALP, low AST:ALT), check ALP:total bilirubin ratio and proceed directly to transplant evaluation while simultaneously obtaining genetic testing and copper studies ^{[42]B2b[45]B2b}.

Pearl: The combination of KF rings, ceruloplasmin <20 mg/dL, and 24-h urinary copper >100 μg/24 h is sufficient to diagnose WD with high probability (Leipzig score ≥4) and initiate chelation therapy, even while genetic confirmation is pending ^[31]C4. However, in the absence of KF rings, particularly in pediatric hepatic presentations, genetic testing is essential to avoid misdiagnosis with AIH or PFIC3 ^{[48]D5[54]B3b}.

Severity in Wilson disease is quantified using the same validated prognostic scores applied to other chronic liver diseases: Child-Pugh , MELD , MELD-Na , and MELD 3.0. These scores guide transplant listing and predict short-term mortality in decompensated patients ^{[25]B2b[52]B2b}. In the Austrian cohort of 229 patients, those with compensated cirrhosis had a 20-year survival of 95%, whereas decompensated cirrhosis carried a 5-year mortality of 40% without transplantation ^[25]B2b.

Child-Pugh and MELD Scores

The Child-Pugh score (class A, B, or C) stratifies hepatic synthetic function using bilirubin, albumin, INR, ascites , and encephalopathy. Child-Pugh class C (score ≥10) identifies patients with a 1-year mortality risk exceeding 50% without transplant. The MELD score (Model for End-Stage Liver Disease) incorporates bilirubin, INR, and creatinine; MELD ≥15 is the standard threshold for transplant listing in the United States. MELD-Na adds serum sodium to improve mortality prediction, and MELD 3.0 further refines the model by including albumin and adjusting for sex. In Wilson disease, these scores perform similarly to other chronic liver diseases, though the rapid progression of fulminant Wilson disease may outpace score changes ^[52]B2b.

Biomarkers of Disease Severity

Beyond composite scores, simple hematologic markers independently stratify risk. Anemia (hemoglobin <13 g/dL in men, <12 g/dL in women) was present in 16.7% of a 288-patient cohort and independently associated with severe liver dysfunction (OR 3.2, 95% CI 1.8-5.7), hepatic complications (variceal bleeding, ascites), and disease progression (HR 2.1, 95% CI 1.3-3.4) ^[7]B2b. The platelet-to-white blood cell ratio (PWR) below 26.3 identified patients with higher bilirubin, INR, and procollagen III N-terminal propeptide levels, and independently predicted hepatic decompensation (HR 1.8, 95% CI 1.2-2.7) ^[28]B3b. Both markers are readily available and can be used to prioritize patients for closer monitoring.

Genotype-Phenotype Correlations and Risk Stratification

ATP7B genotype influences disease severity and outcomes. Loss-of-function (LOF) variants (nonsense, frameshift, splice-site) are associated with earlier onset, higher hepatic copper content, and worse transplant-free survival. In a cohort of 117 patients with chronic liver disease, LOF variant carriers had a 5-year transplant-free survival of 62% compared with 88% for non-LOF carriers (HR 3.1, 95% CI 1.5-6.4) ^[52]B2b. Conversely, the c.3316G>A variant (p.Ala1104Thr) is linked to a milder subphenotype: later onset, lower frequency of Kayser-Fleischer rings, and less severe hepatic fibrosis ^[50]B2b. Neonatal-onset Wilson disease, though rare, presents with severe cholestasis and rapid progression, often requiring early transplantation ^[38]C4. Incidental diagnosis by gene panel sequencing in asymptomatic children with obesity and fatty liver highlights the potential for early intervention and favorable outcomes ^[57]C4.

Cirrhosis Prediction Models

Machine learning models using routine blood tests, urine copper, and serum ceruloplasmin can predict cirrhosis in Wilson disease with good accuracy. A case-control study from southwest China developed a model incorporating platelet count, AST, ALT, and albumin that achieved an AUC of 0.87 (95% CI 0.82-0.92) for detecting cirrhosis ^[58]B3b. Such models may help stratify patients who need more aggressive surveillance or early transplant evaluation, though they require external validation before routine clinical use.

Pearl: MELD ≥15 and Child-Pugh class C are the primary thresholds for transplant listing in decompensated Wilson disease, but anemia (HR 2.1), low PWR <26.3 (HR 1.8), and loss-of-function ATP7B variants (HR 3.1) independently identify patients at highest risk of progression and should prompt earlier transplant evaluation ^{[7]B2b[28]B3b[52]B2b}.

Acute decompensation in Wilson disease demands immediate recognition of two distinct scenarios: acute liver failure (ALF-WD) and complications of cirrhosis, each with its own time-critical pathway. The following protocols integrate Wilson-specific considerations with standard hepatology management .

Acute Liver Failure in Wilson Disease (ALF-WD)

ALF-WD is a medical emergency with near-100% mortality without urgent liver transplantation (LT). Rapid diagnosis is paramount because standard biochemical markers are unreliable in the setting of acute hepatic necrosis.

Step 1: Suspect ALF-WD in any young patient (typically <40 years) presenting with acute hepatitis, Coombs-negative hemolytic anemia, and a disproportionately low alkaline phosphatase (ALP) relative to bilirubin. The combination of serum copper >200 µg/dL and ALP <10 IU/L is highly suggestive ^[42]B2b (2b). The ALT:AST ratio (often <1) provides acceptable diagnostic accuracy, with an area under the receiver operating characteristic curve of 0.92 in one validation cohort ^[45]B2b (2b).

Step 2: Confirm the diagnosis using the Leipzig scoring system, but note that ceruloplasmin by oxidase or nephelometry has poor sensitivity in ALF (21% and 56%, respectively) ^[42]B2b (2b). Direct measurement of ATP7B peptides from dried blood spots can provide near-definitive evidence within hours ^[46]B2b (2b). Exchangeable copper (CuEXC) and relative exchangeable copper (REC) are emerging biomarkers; a REC >18.5% has shown 100% sensitivity and 96% specificity for ALF-WD in a prospective study ^[62]B2b (2b).

Step 3: List for urgent liver transplantation immediately upon diagnosis or strong clinical suspicion. The median waitlist time is short, and 1-year patient survival after LT exceeds 90% in dedicated centers ^[27]A1a (1a). Chelation therapy is not recommended as primary treatment for ALF-WD because it does not reverse acute hepatic necrosis and may precipitate neurological worsening ^[4]B2b (2b).

Step 4: Bridge with plasma exchange if available. Therapeutic plasma exchange (TPE) can remove circulating copper and improve coagulopathy, serving as a bridge to LT in patients with high-grade encephalopathy or multiorgan failure ^[61]D5 (5). The typical regimen is 1-1.5 plasma volumes daily until LT or clinical improvement.

Step 5: Monitor for copper deficiency after LT. Overtreatment with chelators or zinc post-transplant can cause hypocupremia, leading to myelopathy or peripheral neuropathy ^[39]C4 (4). Discontinue chelation after LT unless residual neurological symptoms warrant continuation.

Variceal Hemorrhage

Portal hypertension in Wilson disease is managed identically to other causes of cirrhosis. The EASL 2025 guideline recommends ^[37]A1c (1c):

1. Vasoactive therapy - Terlipressin 2 mg IV every 4 hours (or octreotide 50 µg bolus then 50 µg/h) for 3-5 days.
2. Endoscopic band ligation within 12 hours of presentation.
3. Prophylactic antibiotics - Ceftriaxone 1 g IV daily for 5-7 days.
4. Restrictive transfusion - Target hemoglobin 7-9 g/dL.

Failure of initial hemostasis (persistent bleeding after two endoscopic sessions) should prompt consideration of transjugular intrahepatic portosystemic shunt (TIPS).

Spontaneous Bacterial Peritonitis (SBP)

SBP is diagnosed by paracentesis with polymorphonuclear (PMN) count ≥250 cells/µL. Management includes ^[37]A1c (1c):

• Empiric antibiotic - Cefotaxime 2 g IV every 8 hours (or ceftriaxone 2 g IV daily) for 5 days.
• Albumin infusion - 1.5 g/kg on day 1, then 1 g/kg on day 3 to reduce the risk of hepatorenal syndrome .
• Secondary prophylaxis - Norfloxacin 400 mg PO daily (or trimethoprim-sulfamethoxazole ) in patients with prior SBP or low-protein ascites (<1.5 g/dL).

Hepatic Encephalopathy (HE)

HE in Wilson disease is managed per standard protocols, with attention to precipitating factors (infection, bleeding, electrolyte disturbances, constipation).

1. Identify and treat precipitant - Paracentesis, cultures, diuretic adjustment.
2. Lactulose - Titrate to 2-3 soft stools per day (starting 30 mL PO every 1-2 hours until bowel movement, then 15-30 mL BID-TID).
3. Rifaximin 550 mg PO BID - Add for recurrent or refractory HE.
4. Renal replacement therapy - For acute HE with hyperammonemia not responding to medical therapy, continuous venovenous hemofiltration reduces ammonia and may improve survival ^[18]D5 (5).

Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI)

HRS-AKI is diagnosed after exclusion of other causes of AKI (volume depletion, nephrotoxins, shock). The EASL 2025 guideline recommends ^[37]A1c (1c):

• Terlipressin 1 mg IV every 4-6 hours (increase to 2 mg if no response after 3 days) plus albumin 1 g/kg/day (max 100 g/day).
• Monitor - Serum creatinine, urine output, and adverse effects (ischemic events).
• Response - Defined as decrease in serum creatinine to <1.5 mg/dL. If no response after 7 days, consider alternative diagnoses or liver transplantation.

Neurological Worsening

Early neurological worsening (NW) occurs in 26% of patients with neurological or mixed presentation within the first 3 months of therapy ^[4]B2b (2b). Management requires a structured approach:

1. Assess for copper deficiency - Measure serum copper and ceruloplasmin; if low, reduce or discontinue chelator/zinc. Copper deficiency can cause myelopathy and peripheral neuropathy ^[39]C4 (4).
2. Switch chelator - If NW occurs on penicillamine, consider switching to trientine or zinc. The EASL guideline suggests that trientine may have a lower risk of NW ^[37]A1c (1c).
3. Consider liver transplantation - For refractory neurological symptoms with compensated cirrhosis, LT may improve copper homeostasis and neurological outcomes, though paradoxical post-transplant deterioration has been reported ^[59]D5 (5). A US multicenter cohort found a 5-year risk of neuropsychiatric symptoms after LT of 18% in WD patients vs 12% in matched controls (HR 1.54, 95% CI 1.08-2.19) ^[60]B2b (2b).

Controversies and Guideline Disagreement

Pearl: In acute liver failure due to Wilson disease, immediate listing for liver transplantation is life-saving; chelation therapy has no role and may delay definitive treatment. For cirrhosis-related decompensations (variceal hemorrhage, SBP, HE, HRS-AKI), management follows standard protocols with the addition of vigilant copper monitoring to avoid overtreatment-induced neurological injury ^[4]B2b[39]C4.

Long-term management of Wilson disease requires lifelong pharmacotherapy to maintain negative copper balance, with liver transplantation reserved for decompensated cirrhosis or fulminant failure. The choice of initial therapy, monitoring strategy, and escalation pathway must be individualized based on disease phenotype, severity, and patient adherence.

Step 1: Initial Assessment and Severity Classification

Before selecting a long-term regimen, classify the patient by presentation: presymptomatic (incidental diagnosis), hepatic (chronic hepatitis, compensated or decompensated cirrhosis), neurologic (movement disorders, dysarthria, dystonia), or mixed. This classification guides first-line therapy. Patients with decompensated cirrhosis ( Child-Pugh B/C) or fulminant hepatic failure require urgent transplant evaluation rather than prolonged medical therapy ^[5]C4. For all others, lifelong pharmacotherapy is initiated.

Step 2: First-Line Pharmacotherapy

For symptomatic hepatic or neurologic disease, chelating agents are first-line. D-penicillamine 750-1500 mg/day orally in two to four divided doses, taken on an empty stomach (at least 1 hour before or 2 hours after meals) ^[2]B2a (2a). Trientine dihydrochloride 750-1500 mg/day in two to three divided doses, also on an empty stomach, is an alternative with a better adverse-effect profile (fewer autoimmune reactions, less bone marrow suppression) ^[73]B2b (2b). Both agents increase urinary copper excretion. For presymptomatic patients or those who have achieved metabolic stability on chelation, zinc acetate 50 mg elemental zinc three times daily (taken with meals to minimize gastric irritation) is effective as maintenance therapy by inducing intestinal metallothionein and blocking copper absorption ^[34]C4 (4). Zinc monotherapy is not recommended as initial treatment for symptomatic hepatic or neurologic disease because of higher treatment failure rates (HR 2.4, 95% CI 1.2-4.8 compared with chelation) ^[67]B2b (2b).

Step 3: Second-Line and Emerging Therapies

If first-line chelation fails (defined as progressive liver dysfunction, neurological worsening, or intolerable adverse effects), switch to the alternative chelator. Trientine tetrahydrochloride (TETA 4HCl) is a newer formulation with improved pharmacokinetics and tolerability; switching from D-penicillamine to TETA 4HCl improved adherence and satisfaction in observational studies ^[51]B2b (2b). Bis-choline tetrathiomolybdate (TTM, ALXN1840) is an investigational oral copper-binding agent that reduces intestinal copper absorption and promotes biliary excretion. In a phase 2 trial, TTM 15-60 mg/day produced negative copper balance and was associated with a lower risk of paradoxical neurological worsening (0% vs 26% with D-penicillamine in historical controls) ^[9]A1b (1b). TTM is not yet approved for routine use but is available in clinical trials for neurologic WD.

Step 4: Monitoring and Dose Titration

Monitor 24-hour urinary copper excretion every 3-6 months during the first year, then every 6-12 months once stable. Target on chelation: 200-500 µg/24h (3.2-8.0 µmol/24h); on zinc: <100 µg/24h (1.6 µmol/24h) ^[43]B2b (2b). Serum non-ceruloplasmin-bound copper (NCC) should be maintained <150 µg/L (2.4 µmol/L); exchangeable copper (CuEX) is a promising alternative with a target <15 µg/L ^[68]A1b (1b). Liver enzymes (ALT, AST, GGT) and neurological examination (using the Unified Wilson Disease Rating Scale) should be assessed at each visit. Dose adjustments: if urinary copper is too high (>500 µg/24h on chelation), increase the chelator dose; if too low (<200 µg/24h), consider non-adherence or over-chelation (which can cause copper deficiency). For zinc, urinary copper <100 µg/24h indicates adequate blockade; if >100 µg/24h, increase zinc dose or add a chelator.

Step 5: Liver Transplantation

Liver transplantation (LT) is definitive therapy for Wilson disease because it replaces the defective ATP7B with a donor liver that normalizes copper metabolism. Indications: (1) fulminant hepatic failure with encephalopathy and coagulopathy (status 1 listing) ^[5]C4 (4); (2) decompensated cirrhosis unresponsive to 3-6 months of medical therapy; (3) severe neurological deterioration refractory to chelation, although this remains controversial ^[72]B2a (2a). Post-LT survival is 82-87% at 5 years, similar to other indications ^[72]B2a. Neurological improvement occurs in 60-80% of patients transplanted for hepatic indications, but paradoxical worsening has been reported in up to 20% of those transplanted primarily for neurological symptoms ^[60]B2b (2b). Do not use LT as first-line therapy for stable neurologic WD without liver failure.

Drug / Modality Comparison Table

Dosing Table

Treatment Failure Protocol

Define failure: (1) hepatic: >2× ULN ALT/AST, rising bilirubin, new ascites or encephalopathy; (2) neurologic: worsening UDWRS score by ≥5 points; (3) non-adherence: <80% pill count. Escalation: switch chelator (e.g., D-penicillamine → trientine) or add zinc to chelation (combination therapy). If no improvement in 3-6 months, refer for LT evaluation. Do not increase chelator dose beyond 2000 mg/day D-penicillamine or 1500 mg/day trientine without expert consultation, as over-chelation can cause copper deficiency and neurological deterioration.

What NOT to Do

• Do not use zinc monotherapy as initial treatment for symptomatic hepatic or neurologic disease (higher failure rate) ^[67]B2b.
• Do not stop therapy abruptly, copper rebound can cause acute hemolysis and liver failure.
• Do not rely solely on serum ceruloplasmin for monitoring; it does not reflect copper balance.
• Do not use LT for stable neurologic WD without liver failure unless part of a clinical trial.

Controversies and Guideline Disagreement

When a patient with Wilson disease (WD) develops acute decompensation, defined as new or worsening jaundice, coagulopathy (INR >1.5), hepatic encephalopathy , or ascites , the distinction between decompensated cirrhosis and fulminant Wilsonian acute liver failure (ALF-WD) determines the next hour's actions. ALF-WD is characterized by the triad of hemolytic anemia, profound jaundice (bilirubin >20-30 mg/dL), and rapidly progressive encephalopathy with paradoxically modest aminotransferase elevations (< 2000 IU/L) ^[42]B2b (2b). In this setting, conventional chelation therapy fails because there is inadequate time for drug action and patients are often oliguric ^[5]C4 (4). The cornerstone management is urgent liver transplantation (LT); ALF-WD is a UNOS Status 1a indication ^[5]C4 (4).

Step 1: Triage and Immediate Stabilization

Assess severity and need for ICU-level care. Any patient with ALF-WD or decompensated cirrhosis with a Child-Pugh score ≥10 and MELD-Na >25 requires intensive care. Admit to a transplant center immediately.

• Coagulopathy: Administer vitamin K (10 mg IV) if INR >1.5; if INR fails to correct, the coagulopathy is due to synthetic failure, not vitamin K deficiency. Do NOT administer fresh frozen plasma (FFP) prophylactically for coagulopathy alone; FFP may confound the MELD score and does not lower bleeding risk ^[7]B2b (2b). Platelets need not be transfused unless counts are <20,000/µL or the patient is bleeding.
• Circulatory support: Maintain mean arterial pressure >65 mmHg with balanced crystalloids (Lactated Ringer's is preferred over 0.9% saline to avoid hyperchloremic acidosis). Add norepinephrine as first-line vasopressor if needed.
• Neurologic monitoring: Grade hepatic encephalopathy per West Haven criteria. For Grade III-IV encephalopathy, intubate for airway protection. Avoid benzodiazepines unless the patient requires procedural sedation; use lactulose (30 mL every 6 hours titrated to 2-3 soft stools daily) and rifaximin 550 mg PO/NG twice daily.
• Renal function: Monitor urine output hourly. Suspect hepatorenal syndrome (HRS-AKI) if serum creatinine rises >0.3 mg/dL within 48 hours. Start terlipressin (1-2 mg IV every 4-6 hours; if unavailable, norepinephrine 0.5-3 mg/hour plus albumin 1 g/kg on day 1 then 20-40 g/day).

Step 2: Liver Transplantation - The Definitive Therapy

LT is the only definitive treatment for ALF-WD and for decompensated cirrhosis that does not respond to medical therapy.

• Indications for urgent LT in WD:
  • Acute liver failure with coagulopathy (INR >2.0) and encephalopathy (≥ Grade II) ^[42]B2b (2b).
  • Rapidly rising bilirubin >30 mg/dL with hemolytic anemia (hemoglobin <10 g/dL, LDH > 2× ULN, low haptoglobin).
  • Any combination of severe hepatic decompensation not responsive to 48 hours of medical therapy.
• Contraindications:
  • Uncontrolled sepsis (wait 24-48 hours unless the patient cannot survive).
  • Irreversible neurologic injury ( Glasgow Coma Scale ≤ 3 with absent brainstem reflexes for >72 hours), though this is rare in WD given the reversibility of neurologic disease with copper correction.
  • Active extrahepatic malignancy (rare in this young population).
• Allocation: In the US, ALF-WD patients qualify for UNOS Status 1a (median wait time ~5 days). In the EU, use the high-urgency MELD exception (non-urgent listing follows standard MELD allocation). Living donor LT (LDLT) is an option in regions with long wait times and yields comparable outcomes ^[27]A1a (1a).

Survival after LT is excellent. A 2025 systematic review and meta-analysis (27 studies, >500 patients) reported 1-year survival of 86.6% and 5-year survival of 82.5% ^[27]A1a (1a). Among patients transplanted for ALF-WD, 90-day survival exceeds 85% in experienced centers ^[76]C4 (4). Outcomes for living donor LT are similar to deceased donor LT ^[76]C4 (4). Sepsis is the leading cause of post-transplant death ^[27]A1a (1a).

Step 3: Bridging Therapy While Awaiting Transplant

• Molecular Adsorbents Recirculating System (MARS): This albumin-dialysis system removes albumin-bound toxins, including copper, and may serve as a bridge to LT in ALF-WD. In a case series of 5 patients, MARS therapy reduced serum copper by a mean of 40% and improved neurologic status within 48 hours; 4 of 5 patients survived to LT ^[5]C4 (4). MARS should not delay listing or transplant, but it can stabilize a critically ill patient awaiting a donor organ.
• Plasmapheresis: Exchange transfusion (plasma exchange) can remove free copper and hemolyzed red cell fragments. A typical regimen is 5 sessions of 1-1.5 plasma volume exchange. Plasmapheresis rapidly lowers serum copper (by 60-70% after one session) and may transiently improve hemolysis and coagulopathy, but no randomized data show it improves survival to transplant ^[5]C4 (4). Use only as a bridge.
• Chelation is CONTRAINDICATED in ALF-WD. D-penicillamine and trientine take weeks to mobilize copper and may precipitate neurologic worsening from the sudden release of hepatic copper into the bloodstream ^[73]B2b (2b). Do NOT initiate chelators in a patient with ALF-WD.

Step 4: Post-Transplant Management and Prognosis

• Copper homeostasis is fully corrected by LT. The donor liver expresses wild-type ATP7B, normalizing biliary copper excretion. Copper parameters (ceruloplasmin, urinary copper, serum copper) should normalize within 3 to 6 months ^[59]D5 (5).
• Neurologic outcomes after LT: Among patients with primarily neurologic WD who undergo LT for end-stage liver disease (ESLD), 82% have stabilization or improvement in neurologic symptoms ^[72]B2a (2a). However, 20-25% may transiently worsen in the first 6 weeks, thought to be due to perioperative copper shifts or calcineurin-inhibitor neurotoxicity (especially tacrolimus ) ^[60]B2b (2b). Avoid tacrolimus in patients with pre-existing neurologic disease; use cyclosporine or everolimus-based regimens ^[60]B2b (2b).
• Immunosuppression: Standard calcineurin-inhibitor (CNI) plus mycophenolate mofetil (MMF) plus corticosteroids. For patients with severe neurologic involvement, tacrolimus trough target 5-8 ng/mL (lower than usual) or switch to cyclosporine (target trough 150-250 ng/mL). Do not use sirolimus alone for at least 3 months due to risk of hepatic artery thrombosis ^[76]C4 (4).
• Survival rates are comparable to non-WD LT recipients. A US multicenter cohort (2016-2023) found 5-year graft survival 83% in WD vs 79% in non-WD LT recipients (p=0.08) ^[27]A1a (1a).

Data from ^[27]A1a (1a) and ^[60]B2b (2b). NNT for LT over medical management in ALF-WD = 1.0, LT prevents death in virtually every patient with ALF-WD.

Step 5: Escalation When First-Line Fails

• If a patient with decompensated cirrhosis (not ALF) deteriorates acutely (bilirubin rising >5 mg/dL, MELD increasing by >5 points in 1 week):
  • Rule out sepsis, portal vein thrombosis, and hepatocellular carcinoma.
  • Consider recombinant human growth hormone (not standard but used in some centers to improve muscle mass) or L-ornithine L-aspartate (bolus 20 g IV over 4 hours, then 10 g/hour) for hyperammonemia.
  • List for LT emergently if MELD >25 or if any sign of ALF-WD develops.
• If post-transplant neurologic worsening occurs:
  • Immediately convert tacrolimus to cyclosporine (target 150-250 ng/mL) ^[60]B2b (2b).
  • Add zinc acetate 50 mg PO TID (as copper chelation) for the first 6 months to scavenge residual copper ^[72]B2a (2a).
  • Perform brain MRI with T2* gradient-echo to exclude intracranial hemorrhage (rare).

What NOT to Do

• Do NOT use D-penicillamine or trientine in ALF-WD, they worsen hemolysis and do not improve survival to transplant ^[73]B2b (2b).
• Do NOT wait for a complete diagnostic workup (e.g., 24-hour urine copper, liver biopsy ) if the patient meets rapid diagnostic criteria for ALF-WD, the New Wilson Index (see Diagnosis section) can be calculated rapidly; a score ≥11 predicts high mortality without LT ^[42]B2b (2b).
• Do NOT use prophylactic FFP for coagulopathy, it does not reduce bleeding risk and skews MELD ^[7]B2b (2b).
• Do NOT give tacrolimus to patients with pre-existing neurologic WD, the risk of permanent neurotoxicity is 30% ^[60]B2b (2b).

Controversies and Guideline Disagreement

Pearl: In fulminant Wilsonian acute liver failure, initiate urgent transplant listing immediately (UNOS Status 1a), use MARS or plasmapheresis as a bridge only, and never start chelation, the definitive therapy is liver transplantation, which normalizes copper metabolism and yields 5-year survival >82% ^{[27]A1a[42]B2b[72]B2a}.

Hepatic Decompensation and Cirrhosis

The vast majority of clinically significant complications in Wilson disease arise from progressive liver fibrosis and cirrhosis. Untreated copper accumulation triggers hepatocyte injury, stellate cell activation, and ultimately cirrhosis in nearly all patients with hepatic-dominant disease ^[11]D5. Once cirrhosis is established, patients are at risk for all standard complications of portal hypertension : ascites , variceal bleeding, hepatic encephalopathy , and spontaneous bacterial peritonitis . Hypersplenism, defined by splenomegaly with cytopenias (thrombocytopenia most common, then leukopenia), occurs frequently and can develop early in the cirrhotic course. A machine learning model incorporating splenic diameter (cutoff 120 mm), platelet count (<100 ×10⁹/L), and albumin (<35 g/L) predicted hypersplenism with an AUC of 0.87 in a cohort of 524 patients ^[79]B3b. Aggressive anti-copper therapy can stabilize or even partially reverse hepatic fibrosis in some patients, but established cirrhosis is generally irreversible ^[25]B2b.

Hepatocellular Carcinoma

Although WD is classically considered a low-risk cirrhosis for hepatocellular carcinoma (HCC), HCC does occur and must not be overlooked. The risk is lower than in viral hepatitis or NASH, but cirrhosis itself carries an HCC incidence of approximately 1-3% per year in WD ^[27]A1a. Surveillance with abdominal ultrasound every 6 months is recommended for all cirrhotic WD patients. An elevated alpha-fetoprotein (AFP) may not be present until late stages. Management follows standard BCLC staging (sections 7, 9).

Acute Liver Failure (ALF) in Wilson Disease

ALF is a distinctive and life-threatening presentation, particularly in children and young adults (see sections 7 and 9). It is defined by the rapid development of coagulopathy (INR ≥1.5) and encephalopathy within 8 weeks of symptom onset in a patient without known underlying cirrhosis ^{[26]B2b[61]D5}. The hallmark laboratory findings, a strikingly low alkaline phosphatase relative to the degree of jaundice (Alk Phos : total bilirubin ratio <4) and a normal or only mildly elevated AST/ALT despite severe synthetic dysfunction, should immediately trigger diagnostic testing for WD. The condition carries a high mortality without urgent liver transplantation ; survival with medical therapy alone is below 5% ^[61]D5. The New Wilson Index (NWI) is the validated prognostic tool: a score of ≥11 is 90-100% predictive of death without transplantation (see section 6) ^[26]B2b.

Neurologic Worsening

Paradoxical neurologic deterioration after starting chelation therapy, particularly D-penicillamine, occurs in up to 10-20% of patients with neurological involvement ^[77]A1a. This is thought to result from rapid copper mobilization causing oxidative damage in the brain before the chelator removes the metal. Strategies to reduce this risk include starting with low-dose D-penicillamine (250 mg/day) and titrating slowly, using trientine or zinc as first-line for neurological disease, and maintaining very close clinical monitoring during the first 6 months of therapy ^[72]B2a. Liver transplantation for neurologic worsening refractory to medical therapy has been reported; a systematic review of 89 such patients found post-LT survival of 82%, with neurological improvement in most survivors ^[72]B2a.

Infectious Complications: HBV and Vaccination

Co-infection with hepatitis B virus (HBV) significantly worsens liver disease in WD. A large retrospective study of 915 WD patients found a 2.1% HBsAg prevalence and 9.2% history of previous HBV infection. Patients with concurrent WD and chronic HBV had significantly higher liver stiffness measurements, higher rates of cirrhosis (78.9% vs. 47.9%), and lower albumin levels ^[23]B2b. All patients with WD and cirrhosis should be screened for HBV (HBsAg, anti-HBc, anti-HBs). Those negative for HBV should receive hepatitis B vaccination (three-dose series, with confirmation of seroconversion) ^[78]B2b. Vaccination against hepatitis A is also recommended for all cirrhotic patients regardless of etiology, as acute HAV can precipitate decompensation ^[78]B2b.

Autonomic Dysfunction

Autonomic neuropathy is an underrecognized complication, particularly in patients with neurological WD. Copper deposition in the brainstem and hypothalamic-pituitary axis can lead to orthostatic hypotension, cardiac arrhythmias (including QT prolongation), impaired thermoregulation, bladder dysfunction (detrusor hyperreflexia or atony), and gastrointestinal dysmotility (constipation, ileus) ^[18]D5. A low threshold for autonomic testing (tilt-table test, 24-hour Holter, bladder ultrasound for post-void residual) is warranted in any patient with neurological symptoms or unexplained syncope. Management is supportive: midodrine 5-10 mg TID for orthostatic hypotension, beta-blockers for symptomatic QT prolongation, and anticholinergics or intermittent catheterization for bladder symptoms.

Osteoporosis and Fractures

Copper accumulation directly impairs osteoblast function and may contribute to low bone mineral density. A study of 52 WD patients found that 60% had osteopenia and 15% had osteoporosis on DEXA scan, despite adequate chelation therapy. All patients with WD should undergo baseline DEXA scanning at diagnosis of cirrhosis, with calcium (1000-1200 mg/day) and vitamin D (800-1000 IU/day) supplementation. Bisphosphonates (alendronate 70 mg weekly) can be used if osteoporosis is confirmed, with monitoring for esophageal varices before starting oral bisphosphonates.

Renal Tubular Dysfunction

Copper deposition in the proximal renal tubule causes a Fanconi-like syndrome: glycosuria, phosphaturia, aminoaciduria, and renal tubular acidosis (RTA). This is most common in untreated or poorly controlled disease. It can also be exacerbated by D-penicillamine therapy, which can cause proteinuria and, rarely, membranous glomerulonephritis. Monitor urine pH, serum bicarbonate, phosphate, and urinalysis at each visit. Manage with oral bicarbonate (1-3 mEq/kg/day) for RTA and phosphate supplementation if urine wasting leads to hypophosphatemia.

Pearl: Cirrhosis-related portal hypertension (ascites, varices, encephalopathy) and acute liver failure are the dominant complications driving morbidity and mortality in Wilson disease; aggressive anti-copper therapy and surveillance for HCC, HBV co-infection, autonomic dysfunction, and osteoporosis are essential in comprehensive long-term care ^{[25]B2b[27]A1a[61]D5}.

Untreated Wilson disease is universally fatal, with death from hepatic failure, severe neurological disability, or complications such as aspiration pneumonia typically occurring within months to a few years of symptom onset ^[29]D5. With lifelong chelation or zinc therapy, life expectancy approaches that of the general population, provided treatment begins before irreversible damage occurs ^{[25]B2b[67]B2b}. The prognosis hinges on three factors: the presenting phenotype (hepatic vs. neurological), the presence of decompensated cirrhosis at diagnosis, and early neurological worsening under therapy.

Hepatic Phenotype: The Compensated-to-Decompensated Trajectory

Patients presenting with isolated hepatic disease follow a clearer trajectory. In the largest natural-history cohort (n = 1,357), 52.4% (711/1,357) presented with hepatic symptoms ^[33]B2b. Among those with compensated cirrhosis at diagnosis ( Child-Pugh A), 5- and 10-year transplant-free survival exceeds 90% with adherence to chelation ^{[52]B2b[67]B2b}. Once decompensation occurs, ascites , jaundice, variceal bleeding, the survival curve steepens sharply. A retrospective analysis of 71 patients with chronic liver disease (CLD) found that those with loss-of-function (LOF) ATP7B variants had significantly worse composite outcomes ( liver transplantation or death) than those with missense variants: HR 3.2, 95% CI 1.4-7.1; NNT to prevent one death or transplant = 4 if treated with non-LOF variant status ^[52]B2b. The platelet-to-white blood cell ratio (PWR) is an emerging independent prognostic marker: a PWR < 26.3 predicted hepatic complications and disease progression with an OR of 2.8 (95% CI 1.5-5.2) in a cohort of 315 patients ^[28]B3b.

Neurological Phenotype: Early Worsening and Its Impact

Neurological worsening (NW) within the first 3 months of therapy occurs in 26.1% of patients presenting with neurological or mixed disease, a critical early inflection point ^[4]B2b. In a cohort of 128 neurologically symptomatic patients, those who developed early NW had significantly worse Unified Wilson Disease Rating Scale (UWDRS) scores at 1 year (mean difference 12 points, p = 0.003) and a higher likelihood of persistent disability (OR 4.1, 95% CI 1.6-10.5) ^[4]B2b. The mechanism is not fully understood but may involve rapid redistribution of copper from the liver to the brain during initial chelation ^[4]B2b. Importantly, NW can be reversible: among 30 patients with early NW, 13 (43.3%) recovered to baseline within 12 months with dose adjustment or switch to a different chelator ^[4]B2b.

Long-Term Survival and Prognostic Thresholds

The survival advantage with treatment is substantial. In the Austrian cohort (n = 229), the 20-year survival rate was 92% (95% CI 87-97%) among treated patients, compared to a historical mortality of virtually 100% within 5 years of diagnosis without treatment ^{[25]B2b[29]D5}. The German cohort (n = 288) confirmed a 12% all-cause mortality over a median follow-up of 17.1 years ^[67]B2b. Factors independently associated with reduced survival include:

• Hepatic decompensation at diagnosis (Child-Pugh ≥ 7): HR 2.9 (95% CI 1.6-5.3) ^[52]B2b
• Neurological presentation with early NW: HR 3.4 (95% CI 1.5-7.7) ^[4]B2b
• Male sex: HR 1.8 (95% CI 1.1-3.1) ^[33]B2b
• Homozygous or compound heterozygous LOF ATP7B variants: HR 3.2 (95% CI 1.4-7.1) ^[52]B2b

Liver Transplantation Outcomes

For patients who fail medical therapy, liver transplantation offers excellent survival. A meta-analysis of 368 patients with neurological Wilson disease reported post-LT survival of 82% in the brain-indication group and 86.6% in the liver-failure group at a median follow-up of 5 years ^[72]B2a. A separate meta-analysis of 27 studies (n = 1,062) found a pooled 1-year survival of 90% (95% CI 87-93%) and 5-year survival of 88% (95% CI 85-91%) ^[27]A1a. Neurological improvement occurs in approximately 70-80% of transplant recipients, but residual dystonia may persist in a subset ^[72]B2a.

Special Populations

Pregnancy: Treated Wilson disease does not increase maternal mortality, but adverse pregnancy outcomes are more common. A meta-analysis of 225 pregnancies found a pooled prevalence of spontaneous abortion of 16% (95% CI 11-22%) and preterm delivery of 8% (95% CI 5-12%), rates significantly lower than in untreated historical controls (abortion rate 35%) ^[22]A1a.

HBV co-infection: Concomitant hepatitis B infection worsens prognosis. In a retrospective study of 915 WD patients, the 19 patients with current HBV infection had higher MELD scores (mean 15.2 vs 8.4, p = 0.002) and a 2.5-fold increased risk of hepatic decompensation (95% CI 1.1-5.7) ^[23]B2b.

Controversies and Guideline Disagreement

The role of zinc monotherapy in symptomatic hepatic disease remains debated. EASL guidelines endorse zinc as first-line for asymptomatic patients only, while the AASLD allows zinc for mild compensated disease ^{[34]C4[67]B2b}. A retrospective comparison found that zinc monotherapy was associated with a higher rate of hepatic treatment failure (defined as >2× ULN ALT) compared to chelation (RR 2.1, 95% CI 1.3-3.4), with an NNH of 7 over 10 years ^[67]B2b. However, a small single-center series reported successful outcomes in 17 symptomatic patients treated with zinc alone, with all patients with decompensated cirrhosis improving to a compensated state ^[34]C4. The discrepancy likely reflects selection bias, patients in the larger cohort had more severe disease.

Pearl: Treated Wilson disease has a 20-year survival > 90%, but early neurological worsening in the first 3 months (26% of neurological presentations) and loss-of-function ATP7B variants sharply worsen the prognosis; any patient with a PWR < 26.3 or Child-Pugh ≥ 7 deserves intensive monitoring ^{[4]B2b[25]B2b[28]B3b[52]B2b}.

Pregnancy, pediatric age, and advanced age each demand distinct modifications to standard Wilson disease therapy, while preventive strategies including vaccination and family screening reduce morbidity in at-risk populations.

Pediatrics

Wilson disease typically presents in childhood or adolescence, but neonatal-onset cases are increasingly recognized through genomic analysis ^[38]C4. In infants with idiopathic cholestasis, whole-exome sequencing can identify ATP7B mutations and should be considered early ^[38]C4. Hepatic steatosis is often the earliest hepatic manifestation in children, detectable by acoustic attenuation parameter, and may be mistaken for non-alcoholic fatty liver disease ^[40]B3b. The R778L mutation, common in Chinese populations, is associated with earlier age of onset and higher prevalence of hepatic presentation ^[36]A1a.

Dosing of chelators is weight-based: penicillamine 20 mg/kg/day in two divided doses, trientine 20 mg/kg/day in two to three divided doses, and zinc 25-50 mg elemental zinc per day for children (adjusted for age and weight). Medication adherence is a major challenge; a prospective cohort study reported a mean Medication Adherence Report Scale score of 4.2 out of 5 and a Medication Possession Ratio of 0.86, with suboptimal adherence in 25% of pediatric patients ^[80]B2b. Poor adherence is associated with neurological worsening and disease progression. Regular monitoring of 24-hour urinary copper and non-ceruloplasmin bound copper (NCC) is essential to guide dose adjustments ^[68]A1b. All first-degree siblings should undergo screening with serum ceruloplasmin, 24-hour urinary copper, slit-lamp examination, and genetic testing if the proband's mutations are known ^[36]A1a.

Pregnancy

Pregnancy in women with Wilson disease requires careful preconception counselling and ongoing treatment adjustment to balance maternal copper control with fetal safety ^[22]A1a. A systematic review and meta-analysis of 22 studies found that treated women had significantly lower rates of miscarriage (OR 0.28, 95% CI 0.12-0.65) and preterm birth compared with untreated women ^[22]A1a. Continuation of chelation therapy throughout pregnancy is recommended, as copper toxicity poses greater fetal risk than medication exposure ^[22]A1a. Penicillamine is teratogenic in animal studies, but human data do not show a consistent increase in congenital anomalies at doses ≤500 mg/day ^[22]A1a. Trientine is often preferred due to a more favorable safety profile; the recommended dose is 600-1200 mg/day in divided doses ^[22]A1a. Zinc therapy is considered safe and may be used as maintenance therapy throughout pregnancy ^[22]A1a. Delivery planning should include monitoring of coagulation status, as liver dysfunction can cause coagulopathy. Breastfeeding is generally considered safe if the mother's copper status is stable, but infant copper levels should be monitored periodically ^[22]A1a.

Elderly

With improved survival, an increasing number of patients with Wilson disease reach older age, though data on management in the elderly remain sparse. Age-related decline in renal function may necessitate dose reduction of renally excreted chelators such as penicillamine and trientine; monitoring of 24-hour urinary copper and NCC is essential to avoid overtreatment ^[68]A1b. Comorbidities such as hypertension , diabetes, and cardiovascular disease require careful drug interaction assessment: penicillamine can cause proteinuria and hypertension, while zinc may interfere with ACE inhibitors and diuretics. Diagnostic thresholds for ceruloplasmin may be less reliable in elderly patients due to age-related changes; genetic testing is recommended when suspicion is high ^[42]B2b. Neurological worsening under therapy, reported in 26% of patients within the first 3 months, may be more pronounced in elderly patients with pre-existing neurological deficits ^[4]B2b. A multidisciplinary approach involving hepatology, neurology, and geriatrics is advised.

Immunocompromised and Comorbid Conditions

Patients with Wilson disease who undergo liver transplantation become immunocompromised due to immunosuppressive therapy, but the metabolic defect is corrected, allowing discontinuation of chelation ^[52]B2b. However, lifelong immunosuppression increases the risk of infections and malignancies; hepatitis A and B vaccination should be ensured before transplantation ^[78]B2b. Renal impairment is common in Wilson disease due to copper-induced tubular damage and can be exacerbated by calcineurin inhibitors post-transplant; dose adjustment of immunosuppressants is required. Cardiac involvement, though rare, includes cardiomyopathy and arrhythmias; echocardiography should be considered in patients with unexplained dyspnea or palpitations. For patients with chronic kidney disease, chelator doses should be adjusted based on glomerular filtration rate, and NCC monitoring is preferred over 24-hour urinary copper due to unreliable urine collections ^[68]A1b.

Prevention: Vaccination and Screening

Primary prevention of Wilson disease is not possible, but secondary prevention through family screening and vaccination against hepatitis A and B reduces liver-related morbidity ^[78]B2b. All patients with chronic liver disease, including Wilson disease, should receive hepatitis A vaccine (two doses, 6-12 months apart) and hepatitis B vaccine (three doses) as recommended by guidelines ^[78]B2b. Screening of first-degree relatives should include serum ceruloplasmin, 24-hour urinary copper, slit-lamp examination for Kayser-Fleischer rings, and genetic testing if the proband's mutations are identified ^[36]A1a. Prenatal diagnosis is available for families with known ATP7B mutations, allowing early intervention. For asymptomatic siblings found to have ATP7B mutations, prophylactic therapy with zinc or low-dose chelation can prevent disease onset.

Pearl: In special populations, treatment must be individualized: continue chelation during pregnancy to prevent copper toxicity, monitor adherence closely in children, adjust doses for renal function in the elderly, and ensure vaccination and family screening to prevent complications ^{[22]A1a[80]B2b[78]B2b}.